These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31490070)

  • 1. Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
    Hu J; Tian CQ; Damaneh MS; Li Y; Cao D; Lv K; Yu T; Meng T; Chen D; Wang X; Chen L; Li J; Song SS; Huan XJ; Qin L; Shen J; Wang YQ; Miao ZH; Xiong B
    J Med Chem; 2019 Sep; 62(18):8642-8663. PubMed ID: 31490070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
    Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
    Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.
    Zhao Y; Zhou B; Bai L; Liu L; Yang CY; Meagher JL; Stuckey JA; McEachern D; Przybranowski S; Wang M; Ran X; Aguilar A; Hu Y; Kampf JW; Li X; Zhao T; Li S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jul; 61(14):6110-6120. PubMed ID: 30015487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 8-Methyl-pyrrolo[1,2-
    Li Z; Xiao S; Yang Y; Chen C; Lu T; Chen Z; Jiang H; Chen S; Luo C; Zhou B
    J Med Chem; 2020 Apr; 63(8):3956-3975. PubMed ID: 32208600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
    Zhao L; Wang Y; Cao D; Chen T; Wang Q; Li Y; Xu Y; Zhang N; Wang X; Chen D; Chen L; Chen YL; Xia G; Shi Z; Liu YC; Lin Y; Miao Z; Shen J; Xiong B
    J Med Chem; 2015 Feb; 58(3):1281-97. PubMed ID: 25559428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
    Zhang M; Zhang Y; Song M; Xue X; Wang J; Wang C; Zhang C; Li C; Xiang Q; Zou L; Wu X; Wu C; Dong B; Xue W; Zhou Y; Chen H; Wu D; Ding K; Xu Y
    J Med Chem; 2018 Apr; 61(7):3037-3058. PubMed ID: 29566488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.
    Yoo M; Yoo M; Kim JE; Lee HK; Lee CO; Park CH; Jung KY
    Arch Pharm Res; 2018 Jan; 41(1):46-56. PubMed ID: 29103140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel phenanthridin-6(5H)-one derivatives as potent and selective BET bromodomain inhibitors: Rational design, synthesis and biological evaluation.
    Zhi Y; Wang S; Huang W; Zeng S; Liang M; Zhang C; Ma Z; Wang Z; Zhang Z; Shen Z
    Eur J Med Chem; 2019 Oct; 179():502-514. PubMed ID: 31276895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor.
    Hagihara S; Ishizawa K; Soga K; Honjo T; Takai S; Kawano Y; Kikuchi M; Nishidate A; Matsumoto F; Murase M; Hashimoto N; Sasaki C; Miyaguchi I; Okada O; Akashi T; Nakayama S; Ogasawara Y; Endo J
    Bioorg Med Chem Lett; 2024 Sep; 109():129849. PubMed ID: 38876177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family.
    Fang L; Hu Z; Yang Y; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2021 Jun; 39():116133. PubMed ID: 33862375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1.
    Wu Q; Chen DQ; Sun L; Huan XJ; Bao XB; Tian CQ; Hu J; Lv KK; Wang YQ; Xiong B; Miao ZH
    Biochem Pharmacol; 2021 Mar; 185():114435. PubMed ID: 33539817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).
    Bradbury RH; Callis R; Carr GR; Chen H; Clark E; Feron L; Glossop S; Graham MA; Hattersley M; Jones C; Lamont SG; Ouvry G; Patel A; Patel J; Rabow AA; Roberts CA; Stokes S; Stratton N; Walker GE; Ward L; Whalley D; Whittaker D; Wrigley G; Waring MJ
    J Med Chem; 2016 Sep; 59(17):7801-17. PubMed ID: 27528113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping.
    Zhang Z; Gu L; Wang B; Huang W; Zhang Y; Ma Z; Zeng S; Shen Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):808-817. PubMed ID: 30879350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and lead identification of quinazoline-based BRD4 inhibitors.
    Yang SM; Urban DJ; Yoshioka M; Strovel JW; Fletcher S; Wang AQ; Xu X; Shah P; Hu X; Hall MD; Jadhav A; Maloney DJ
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3483-3488. PubMed ID: 30268702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.